OBJECTIVE: Smoking is generally accepted as a factor that affects the disease course in inflammatory bowel disease patients. Whether these effects can be contributed to the immunomodulatory effects of nicotine via nicotinic acetylcholine receptor (nAChR) activation is unclear. As previous data suggest that the α7 nicotinic acetylcholine receptor (CHRNA7) and its duplicated variant CHRFAM7A may specifically participate in the inflammatory response of monocytes, we evaluated whether repeated nicotine exposure or smoking affects monocyte CHRNA7 and CHRFAM7A expression and cholinergic immunomodulation. METHODS: The human monocyte cell line THP-I was incubated with nicotine for different time points before endotoxin exposure. In a pilot volunteer study using smoking (n = 4) and nonsmoking (n = 7) individuals, vagal output was stimulated by olive oil administration after which monocytes were analyzed for nicotinic receptor expression. Serum tumor necrosis factor (TNF) levels were determined using ELISA and expression levels of the nAChR subunits CHRNA7, CHRNB2 or CHRFAM7A were analyzed using QPCR. RESULTS: Repeated nicotine exposure upregulated CHRNA7 expression on THP-I monocytes and led to an enhanced potential of α7 nAChR agonist GSK1345038A to reduce TNF levels. Furthermore, CHRNA7 was only detectable in isolated blood monocytes of smokers. On the other hand, the expression of CHRFAM7A and CHRNB2 was not affected by nicotine exposure. Lipopolysaccharides-induced TNF secretion was inhibited by nicotinic receptor activation in THP-I monocytes, but this response was not consistently seen in blood monocytes from smoking individuals. CONCLUSIONS: We conclude that CHRNA7 expression on blood monocytes is upregulated in smoking individuals, which may contribute to cholinergic immunomodulation.
OBJECTIVE: Smoking is generally accepted as a factor that affects the disease course in inflammatory bowel diseasepatients. Whether these effects can be contributed to the immunomodulatory effects of nicotine via nicotinic acetylcholine receptor (nAChR) activation is unclear. As previous data suggest that the α7 nicotinic acetylcholine receptor (CHRNA7) and its duplicated variant CHRFAM7A may specifically participate in the inflammatory response of monocytes, we evaluated whether repeated nicotine exposure or smoking affects monocyte CHRNA7 and CHRFAM7A expression and cholinergic immunomodulation. METHODS: The human monocyte cell line THP-I was incubated with nicotine for different time points before endotoxin exposure. In a pilot volunteer study using smoking (n = 4) and nonsmoking (n = 7) individuals, vagal output was stimulated by olive oil administration after which monocytes were analyzed for nicotinic receptor expression. Serum tumor necrosis factor (TNF) levels were determined using ELISA and expression levels of the nAChR subunits CHRNA7, CHRNB2 or CHRFAM7A were analyzed using QPCR. RESULTS: Repeated nicotine exposure upregulated CHRNA7 expression on THP-I monocytes and led to an enhanced potential of α7 nAChR agonist GSK1345038A to reduce TNF levels. Furthermore, CHRNA7 was only detectable in isolated blood monocytes of smokers. On the other hand, the expression of CHRFAM7A and CHRNB2 was not affected by nicotine exposure. Lipopolysaccharides-induced TNF secretion was inhibited by nicotinic receptor activation in THP-I monocytes, but this response was not consistently seen in blood monocytes from smoking individuals. CONCLUSIONS: We conclude that CHRNA7 expression on blood monocytes is upregulated in smoking individuals, which may contribute to cholinergic immunomodulation.
Authors: Mauricio Rosas-Ballina; Peder S Olofsson; Mahendar Ochani; Sergio I Valdés-Ferrer; Yaakov A Levine; Colin Reardon; Michael W Tusche; Valentin A Pavlov; Ulf Andersson; Sangeeta Chavan; Tak W Mak; Kevin J Tracey Journal: Science Date: 2011-09-15 Impact factor: 47.728
Authors: Susanne A Snoek; Marleen I Verstege; Esmerij P van der Zanden; Nigel Deeks; David C Bulmer; Michael Skynner; Kevin Lee; Anje A Te Velde; Guy E Boeckxstaens; Wouter J de Jonge Journal: Br J Pharmacol Date: 2010-05 Impact factor: 8.739
Authors: W J Sandborn; W J Tremaine; K P Offord; G M Lawson; B T Petersen; K P Batts; I T Croghan; L C Dale; D R Schroeder; R D Hurt Journal: Ann Intern Med Date: 1997-03-01 Impact factor: 25.391
Authors: David J van Westerloo; Ilona A Giebelen; Sandrine Florquin; Marco J Bruno; Gregory J Larosa; Luis Ulloa; Kevin J Tracey; T van der Poll Journal: Gastroenterology Date: 2006-05 Impact factor: 22.682
Authors: Y Villiger; I Szanto; S Jaconi; C Blanchet; B Buisson; K-H Krause; D Bertrand; J-A Romand Journal: J Neuroimmunol Date: 2002-05 Impact factor: 3.478
Authors: Emily G Severance; Faith B Dickerson; Cassie R Stallings; Andrea E Origoni; Anne Sullens; Eric T Monson; Robert H Yolken Journal: J Neural Transm (Vienna) Date: 2008-12-11 Impact factor: 3.575
Authors: Martina Di Giovangiulio; Goele Bosmans; Elisa Meroni; Nathalie Stakenborg; Morgane Florens; Giovanna Farro; Pedro J Gomez-Pinilla; Gianluca Matteoli; Guy E Boeckxstaens Journal: Mol Med Date: 2016-06-14 Impact factor: 6.354
Authors: Félix M Ramos; Manuel Delgado-Vélez; Ángel L Ortiz; Carlos A Báez-Pagán; Orestes Quesada; José A Lasalde-Dominicci Journal: J Neurovirol Date: 2015-11-13 Impact factor: 2.643
Authors: Lorise C Gahring; Elena Y Enioutina; Elizabeth J Myers; Gerald J Spangrude; Olga V Efimova; Todd W Kelley; Petr Tvrdik; Mario R Capecchi; Scott W Rogers Journal: PLoS One Date: 2013-03-01 Impact factor: 3.240
Authors: Kathleen C Brown; Haley E Perry; Jamie K Lau; Dennie V Jones; Joseph F Pulliam; Brent A Thornhill; Clayton M Crabtree; Haitao Luo; Yi Charlie Chen; Piyali Dasgupta Journal: J Biol Chem Date: 2013-10-02 Impact factor: 5.157
Authors: Coral M Capó-Vélez; Manuel Delgado-Vélez; Carlos A Báez-Pagán; José A Lasalde-Dominicci Journal: Cell Mol Neurobiol Date: 2018-07-14 Impact factor: 4.231